Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab

Stroke

Volumn 47, Issue 7, 2016, Pages 1936-1938

  Berrouschot, Jörg ^a   Stoll, Anett ^a   Hogh, Theresa ^a   Eschenfelder, Christoph Cyrill ^b  

^a Klinikum Altenburger Land GmbH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

anticoagulants; antidotes; dabigatran; idarucizumab; stroke

Indexed keywords

ALTEPLASE; DABIGATRAN; IDARUCIZUMAB; ANTIDOTE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ANOMIA; ANTICOAGULATION; APHASIA; ARTICLE; ATRIAL FIBRILLATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE REPORT; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG POTENTIATION; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; HYPERTENSION; IN VITRO STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STROKE PATIENT; THROMBIN TIME; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTAGONISTS AND INHIBITORS; COMPLICATION; CONVALESCENCE; DIET THERAPY; INFARCTION, MIDDLE CEREBRAL ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESIS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIDOTES; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DABIGATRAN; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; PARESIS; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84974777785     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.013550     Document Type: Article

References (14)

1. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, American Heart Association Stroke Council and Council on Epidemiology and Prevention Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016 47 581 641. doi: 10.1161/STR.0000000000000086.
2. Actilyse prescribing information 2015 Boehringer Ingelheim Limited
3. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007 38 1655 1711. doi: 10.1161/STROKEAHA.107.181486.
4. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 44 870 947. doi: 10.1161/STR.0b013e318284056a.
5. Idarucizumab (praxbind)-An antidote for dabigatran. The Medical Letter on Drugs and Therapeutics 2015 57 157 158
6. Fda approved drugs database praxbind prescribing information 2015. Boehringer Ingelheim International GmbH
7. Burness CB, Idarucizumab: first global approval. Drugs 2015 75 2155 2161. doi: 10.1007/s40265-015-0508-5.
8. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI, Idarucizumab: the antidote for reversal of dabigatran. Circulation 2015 132 2412 2422. doi: 10.1161/CIRCULATIONAHA.115.019628.
9. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Idarucizumab for dabigatran reversal. N Engl J Med 2015 373 511 520. doi: 10.1056/NEJMoa1502000.
10. Schiele F, van Ryn J, Litzenburger T, Ritter M, Seeliger D, Nar H, Structure-guided residence time optimization of a dabigatran reversal agent. MAbs 2015 7 871 880. doi: 10.1080/19420862.2015.1057364.
11. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, A specific antidote for dabigatran: functional and structural characterization. Blood 2013 121 3554 3562. doi: 10.1182/blood-2012-11-468207.
12. Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015 114 198 205. doi: 10.1160/TH15-03-0192.
13. van Ryn J, Schurer J, Fischer D, Abstract wp73: no influence of dabigatran or its specific reversal agent, idarucizumab, on rtpa-induced thrombolysis of clots in human plasma: An in vitro study. Stroke 2016 47 AWP73
14. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015 113 943 951. doi: 10.1160/TH14-12-1080.